Abstract

RationaleBenzodiazepines have been extensively investigated in experimental settings especially after single administration, which mostly revealed effects on unpredictable threat (U-threat) rather than predictable threat (P-threat). Given the need for pharmacological alternatives with a preferable side-effect profile and to better represent clinical conditions, research should cover also other anxiolytics and longer application times.ObjectivesThe present study compared the acute and short-term effects of the translocator protein 18 kDa (TSPO) ligand etifoxine and the benzodiazepine alprazolam on P-threat and U-threat while controlling for sedation.MethodsSixty healthy male volunteers, aged between 18 and 55 years, were randomly assigned to receive a daily dose of either 150 mg etifoxine, 1.5 mg alprazolam, or placebo for 5 days. On days 1 and 5 of intake, they performed a NPU-threat task including neutral (N), predictable (P), and unpredictable (U) conditions, while startle responsivity and self-reports were studied. Sedative effects were assessed using a continuous performance test.ResultsNeither alprazolam nor etifoxine affected startle responsivity to U-threat on any of the testing days. While etifoxine reduced the startle response to P-threat on day 1 of treatment for transformed data, a contrary effect of alprazolam was found for raw values. No effects on self-reports and no evidence of sedation could be observed for either drug.ConclusionsNone of the anxiolytic substances had an impact on startle potentiation to U-threat even after several days of intake. The effects of the anxiolytics on startle responsivity to P-threat as well as implications for future studies are discussed.

Highlights

  • Benzodiazepines rank among the most frequently prescribed substances for the treatment of anxiety disorders (Donoghue and Lader, 2010)

  • The startle response to P-threat was reduced by etifoxine on the first treatment day

  • Deviant results were shown for raw data analysis yielding a significant effect only for alprazolam

Read more

Summary

Introduction

Benzodiazepines rank among the most frequently prescribed substances for the treatment of anxiety disorders (Donoghue and Lader, 2010). While being effective and fast acting, they bear the risk of side effects including sedation, risk of addiction potential, and withdrawal symptoms, especially after long-term application (Lader, 2011) They are not considered as first-choice treatments like antidepressants or psychotherapy (Bandelow et al 2015). With regard to the potential for the pharmacological treatment of anxiety disorders, novel alternatives should aim for combining the efficacy and fast onset of existing compounds with lacking the most critical side effects. Interesting candidates in this context are ligands of the translocator protein 18 kDa (TSPO) (Papadopoulos et al 2006; Nothdurfter et al 2012; Rupprecht et al 2009, 2010). Genetically determined disruption of TSPO function has been shown to predispose separation anxiety (Costa et al 2009) or bipolar disorder (Colasanti et al 2013)

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call